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Acute respiratory distress syndrome (ARDS) is common among mechanically ventilated 
children and accompanies up to 30% of all pediatric intensive care unit deaths. Though 
ARDS diagnosis is based on clinical criteria, biological markers of acute lung damage 
have been extensively studied in adults and children. Biomarkers of inflammation, alveo-
lar epithelial and capillary endothelial disruption, disordered coagulation, and associated 
derangements measured in the circulation and other body fluids, such as bronchoalveo-
lar lavage, have improved our understanding of pathobiology of ARDS. The biochemical 
signature of ARDS has been increasingly well described in adult populations, and this 
has led to the identification of molecular phenotypes to augment clinical classifications. 
However, there is a paucity of data from pediatric ARDS (pARDS) patients. Biomarkers 
and molecular phenotypes have the potential to identify patients at high risk of poor out-
comes, and perhaps inform the development of targeted therapies for specific groups 
of patients. Additionally, because of the lower incidence of and mortality from ARDS in 
pediatric patients relative to adults and lack of robust clinical predictors of outcome, there 
is an ongoing interest in biological markers as surrogate outcome measures. The recent 
definition of pARDS provides additional impetus for the measurement of established and 
novel biomarkers in future pediatric studies in order to further characterize this disease 
process. This chapter will review the currently available literature and discuss potential 
future directions for investigation into biomarkers in ARDS among children.
Keywords: biomarkers, acute lung injury, ARDS, PARDS, pediatrics, critical care, surrogate outcomes, molecular 
phenotypes
iNTRODUCTiON
Acute lung disease or injury is a frequent contributor to admission to pediatric (PICU) and/or 
neonatal (NICU) intensive care units. At least 30% of children require invasive mechanical ventila-
tion, and those who develop the acute respiratory distress syndrome (ARDS) may account for as 
much as 30% of all PICU mortality (1, 2). As in adults, acute lung injury (ALI) in children occurs 
as a consequence of various direct (e.g., infectious pneumonia, bronchiolitis, aspiration, traumatic 
lung contusion) or indirect (e.g., sepsis, shock, massive blood transfusion, non-pulmonary trauma) 
injuries to the lung. Similar events can lead to the infant respiratory distress syndrome (RDS), 
with surfactant deficiency and lung immaturity as underlying conditions (3). ARDS by the most 
recent Berlin definition (4), formerly known as the severe subgroup of “acute lung injury,” can 
result from these processes (5). Though a new pediatric-specific consensus definition for pedi-
atric ARDS (pARDS) has been published (6), the vast majority of available studies in children 
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are based on prior definitions. Clinically, ARDS is characterized 
by non-cardiogenic pulmonary edema, resulting in hypoxemia 
and infiltrates on chest radiography (7). Histopathologically, 
ARDS is characterized by a dysregulated lung inflammation and 
protein-rich interstitial and alveolar edema, as a consequence of 
enhanced permeability or disruption of the alveolar– capillary 
barrier (7). Disruption of the alveolar–capillary barrier can 
thereby lead to protein leak and transmigration of soluble 
proteins and other biological mediators both from and to the 
systemic circulation (8).
There has been growing literature resulting from interest in 
studying biological markers of acute lung diseases, including 
ARDS, in both the plasma or serum as well as bronchoalveolar 
lavage (BAL) fluid, with the hope to better elucidate patho-
physiological mechanisms of ALI and to identify the potential 
markers of severity and outcome (6). The vast majority of these 
investigations have involved adult patients, and findings have 
subsequently been extrapolated to children. Large pediatric 
studies have been infrequent and limited in their findings 
because of the small numbers of ARDS patients, heterogeneity of 
underlying disease processes leading to pARDS, and the overall 
low mortality of pARDS. Multiple clinical outcome predictors 
in pARDS have been identified, with findings indicating that 
the severity of oxygenation defects, dead space fraction, organ 
failures, and underlying immunodeficiency are important 
factors (2, 9–11). However, the utility of clinical predictors is 
limited by the relatively low and decreasing rates of mortality 
in pARDS (12). Additionally, some clinical predictors may have 
less specificity for ARDS than molecular markers and have not 
yet led to the development of novel therapies targeting specific 
patient groups. Therefore, in addition to clinical findings there 
has been an ongoing interest in using biomarkers, specifically 
of endothelial and epithelial integrity/injury, coagulation/
fibrinolysis, inflammation, and inflammation-associated cel-
lular derangements, as surrogate markers of patient outcomes 
in pARDS.
The main focus of this review is to assess the current knowl-
edge of biomarker patterns in acute lung disease/injury and their 
association to patient outcomes, with a specific focus on the 
pediatric and neonatal patient population.
BiOMARKeR SUBGROUPS
Proteins and other biomarkers measured in blood or BAL fluid 
that have been reported in the literature and have the potential 
to serve as biological markers are presented here in a systematic 
manner based on their pathogenesis: inflammation, coagulation, 
epithelial, endothelial, surfactant, and non-protein markers. 
Plasma or serum biomarkers are favored in many instances over 
biomarkers from BAL fluid due to the relatively easy availability of 
blood samples. Additionally, in many instances, unstable patients 
with lung injury may not tolerate the BAL procedure. Plasma and 
serum biomarkers that have been studied in the pediatric or neo-
natal populations are presented in Table 1 and BAL fluid markers 
in Table 2. Most biomarkers studied to date are protein-based, 
but we will also discuss several non-protein biomarker groups 
that have the potential to add to our understanding of pARDS.
inflammation Pathways
Some of the most intensely studied protein biomarkers of criti-
cal illness belong to the large family of inflammatory cytokines 
dubbed interleukins (ILs). Many of the members of this family 
have been studied in other forms of critical illnesses, some of 
which are recognized ARDS risk factors, such as sepsis, trauma, 
or postoperative states. IL-1 and its antagonist IL-1 receptor 
antagonist (IL-1ra) have been found in BAL fluid and correlate 
with ARDS severity and outcome in adults (74). In children, 
IL-1 has not been correlated with ARDS, though it significantly 
elevated among a cohort of children with severe acute respiratory 
syndrome (SARS) (16). IL-6 is another important inflammatory 
cytokine, and elevated plasma and BAL fluid levels have been 
associated with ARDS in adults (74–77) as well as plasma in 
children and neonates with RDS (14, 18, 19). In studies of chil-
dren with burn-related inhalation injury and severe influenza, 
IL-6 levels were associated with increased mortality (14, 17), 
in agreement with adult data (78). IL-1 and IL-6 levels in BAL 
fluid were also both found to be elevated in premature babies 
with RDS and were correlated with the development of chronic 
lung disease (CLD) (56, 58, 59). As a biomarker of response 
to therapy, IL-6 was recently found to decrease in response to 
glucocorticoid (GC) therapy in a randomized trial of GC therapy 
in children (20). The relationship of the inflammatory cytokine 
response to ventilation strategies was also demonstrated in the 
landmark ARDSNet trial of low-tidal-volume ventilation, where 
IL-6 and IL-8 levels were observed to decrease in the low-tidal-
volume group compared with the controls (79, 80). IL-8, another 
inflammatory cytokine, is elevated in the plasma and BAL fluid 
of adults with ARDS and is associated with organ failure and 
mortality in adults (75, 77, 81). In children with ARDS and RDS, 
the plasma and BAL fluid IL-8 levels are elevated (21, 58), but 
the relationship with outcomes remains less clear. However, in a 
cohort that included critically ill children with influenza and 27% 
ARDS prevalence, non-survivors had dramatically higher plasma 
IL-8 concentrations than survivors, suggesting a possible role as 
a prognostic factor in pARDS more generally (14). IL-10 is a 
major anti-inflammatory cytokine, and elevations in plasma and 
BAL fluid have been associated with the development of ARDS 
as well as with ARDS mortality in adults (80, 82, 83). It appears 
that an early rise in IL-10 at the onset of ARDS is followed by 
normalization of levels over the first 21 days of illness (74), and 
this pattern was also seen in children with ARDS, both with and 
without steroid therapy (16, 20). IL-10 is elevated in newborns 
with RDS (22), independent of gestational age, and has also been 
associated with increased development of ARDS and increased 
mortality among pediatric burn patients with inhalation injury 
(17). Several other cytokines of the IL family, including IL-4, IL-7, 
and IL-13 (each in pediatric burn patients) (17), IL-12 (RDS) 
(22), and IL-17 (pARDS) (20), have been associated with the out-
comes from lung injury in individual studies. Comparing non-
survivors to survivors from the previously mentioned cohort of 
severe influenza patients, the investigators also found significant 
elevations in granulocyte–macrophage colony-stimulating factor, 
interferon-inducible protein 10, monocyte chemotactic protein 
1, and macrophage inflammatory protein 1α (14), though these 
findings have yet to be reproduced in other pediatric cohorts.
TABLe 1 | Serum/plasma biomarkers.
Biomarker Full name Finding in children Reference
inflammation
CRP C-reactive protein – Elevated in children with ARDS and associated with mortality and fewer VFDs (13)
GM-CSF Granulocyte–Macrophage colony-
stimulating factor
– Elevated in severe influenza non-survivors (27% had ARDS) (14)
HNE Human neutrophil elastase – Elevated in RSV bronchiolitis compared with controls, not correlated with disease 
severity
(15)
IL-1 Interleukin 1 – Elevated in SARS patients relative to control (16)
IL-4 Interleukin 4 – Early elevation associated with ARDS and duration of ventilation in burn patients (17)
IL-6 Interleukin 6 – Elevated in children with ARDS compared to control
– Elevated in severe influenza non-survivors (27% had ARDS)
– Decreased with steroid administration in ARDS trial and in SARS patients
– Increased in burn patients with inhalation injury who did not survive, associated with 
ARDS, ventilation
(14, 16–20)
IL-7 Interleukin 7 – Decreased in burn patients with inhalation injury who did not survive, associated 
with ARDS, ventilation
(17)
IL-8 Interleukin 8 – Elevated in severe influenza non-survivors (27% had ARDS)
– Elevated in BAL and plasma in ARDS vs. control
(14, 21)
IL-10 Interleukin 10 – Elevated in newborns with RDS independent of gestational age
– Increased in burn patients with inhalation injury who did not survive, associated with 
ARDS, ventilation
– Associated with O2 use at PICU discharge and plateau pressure in ARDS
(17, 20, 22)
IL-12 Interleukin 12 – Decreased in newborns with RDS independent of gestational age
– Negative predictor of plateau pressure at ARDS day 7
(20, 22)
IL-13 Interleukin 13 – Increased in burn patients with inhalation injury who did not survive, associated with 
ARDS, ventilation
(17)
IL-17 Interleukin 17 – Elevations associated with O2 requirement at ICU discharge in children with ARDS (20)
IP-10 IFN-inducible protein 10 (aka CXCL10) – Elevated in severe influenza non-survivors (27% had ARDS) (14)
sL-selectin Soluble L-selectin – Decreased in infants with RDS who developed BPD, increases with steroid therapy (23)
MCP-1 Monocyte chemotactic protein 1 – Elevated in severe influenza non-survivors (27% had ARDS) (14)
MIP-1alpha Macrophage inflammatory protein 1 alpha – Elevated in severe influenza non-survivors (27% had ARDS) (14)
TNF-α Tumor necrosis factor alpha – Associated with IL-1 and IL-10 levels in children with ARDS (20)
Coagulation and fibrinolysis
AT-III Antithrombin-III – Decreased to <70% in non-survivors among pediatric ARDS patients (24)
PAI-1 Plasminogen activator inhibitor 1 – Associated with mortality and fewer VFDs in children with ARDS
– Significantly elevated in children with ARDS, septic shock, and purpura
(25, 26)
suPAR Soluble urokinase-type plasminogen 
activator receptor
– Elevated in newborns who progress to BPD and associated with disease severity
– Elevated in children with pneumonia and associated with severity
(27, 28)
epithelium
CC16/CC10 Clara cell secretory protein – Elevated in ventilated preterm neonates
– Cord blood levels decreased in RDS and BPD
– Decreased in newborns who develop BPD
(19, 29, 30)
sICAM-1 Soluble intercellular adhesion molecule 1 – Elevated in children with ALI
– Associated with mortality and length of ventilation in children with ARDS
– Increases after lung recruitment maneuver are associated with non-response in 
children with ARDS
(31–34)
KL-6 Krebs von den Lungen-6 – Elevated in PICU patients with ARDS compared with sepsis/trauma and associated 
with mortality and LOS
– Elevated in infants with RSV bronchiolitis and associated with disease severity
(35, 36)
sRAGE Soluble receptor for advanced glycation 
end products
– Elevated in infants with bronchiolitis
– Elevated in infants with RDS
– Elevation predicts ALI in post-op cardiac surgery patients and associated with 
prolonged ventilation
(37–39)
endothelium
Ang-2 Angiopoietin-2 – Elevations associated with mortality in children with ARDS. Increases predict ARDS 
mortality in bone marrow transplant
(40)
sE-selectin Soluble E-selectin – Elevated in children with ALI compared with controls and associated with length of 
ventilation and mortality
– Elevated in cord blood and plasma from infants with RDS who developed BPD
– Decreases in response to steroid therapy in infants with RDS
(23, 41–43)
ET-1 Endothelin 1 – Elevated in cord blood from infants with RDS and correlated with severity
– Elevated in children with ARDS and associated with mortality
(18, 44)
sTM Soluble thrombomodulin – Elevated and associated with mortality in children with indirect ARDS
– Associated with organ failure in all children with ARDS
(45)
(Continued)
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Biomarker Full name Finding in children Reference
VEGF Vascular endothelial growth factor – Decreased in premature infants with RDS, also decreased VEGF to sVEGF-R ratio
– Elevations associated with decreased pulmonary deterioration in premature infants
(46, 47)
sVEGF-R Soluble vascular endothelial growth factor 
receptor
– Increased in premature infants with RDS (46)
vWF Von Willebrand factor – Early elevation in pediatric ARDS associated with mortality and length of ventilation (48)
Surfactant proteins
SP-A Surfactant protein A – Elevated in children with ARDS (21)
SP-B Surfactant protein B – Elevated in children with ARDS (21)
SP-D Surfactant protein D – Elevated in children with ARDS
– Elevated in children with bronchopneumonia
– Elevated in infants with viral bronchiolitis
(21, 49–51)
Other proteins
AQP-5 Aquaporin-5 – Elevated in neonatal RDS and correlated disease severity (38)
BNP B-type natriuretic peptide – Elevated in non-surviving children with ALI
– Elevations associated with prolonged ventilation, worse hypoxia, need for inotropes 
in children with ALI
(52)
sFAS-L Soluble FAS ligand – Elevated in infants with RSV bronchiolitis (53)
sST2 Soluble suppression of tumorigenicity 2 – Elevated in newborns who progress to BPD (27)
Non-protein biomarkers
PGE Prostaglandin E – Elevated in RDS with decreased PGE to PGF ratio (54)
PGF Prostaglandin F – Elevated in RDS with decreased PGE to PGF ratio (54)
ALI, acute lung injury; ARDS, acute respiratory distress syndrome; BPD, bronchopulmonary dysplasia; CLD, chronic lung disease; LOS, length of stay; O2, oxygen; RDS, respiratory 
distress syndrome; SARS, severe acute respiratory syndrome; VFD, ventilator-free days.
TABLe 1 | Continued
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Tumor necrosis factor alpha (TNF-α) and its soluble receptors 
(sTNFR-1 and sTNFR-2) have diverse effects on the immune 
system and have been associated with both ARDS development 
and outcomes in adults (74, 78). The role of TNF-related activity 
in pARDS is less clear. A study of healthy neonates subjected to 
mechanical ventilation found increases in TNF-α and IL-6 in 
tracheal aspirate fluid (60) and plasma TNF-α levels were corre-
lated with other cytokine levels, including IL-1α and IL-10 among 
children in a randomized controlled trial of corticosteroids for 
ARDS (20), suggesting a possible role in pARDS.
Another group of inflammation-related proteins that has been 
of significant interest is the matrix metalloproteinase (MMP) 
family. Through their activity in the breakdown and remodeling 
of tissue matrices (84), these proteins may have direct functional 
significance in addition to their utility as biomarkers. MMPs 
can be produced by multiple cell types, including immune cells, 
fibroblasts, and epithelial cells, and many different subgroups 
of MMPs have been identified and classified based on their 
substrates (85). Several studies have found associations between 
levels of MMP-8, MMP-9, MMP-10, and the MMP antagonist 
tissue inhibitor of metalloproteinases 1 (TIMP-1) and outcomes 
from sepsis in adults (86–88), while one study in a mixed popula-
tion of ventilated adults found that serum levels of TIMP-1 and 
MMP-8 were associated with decreased survival and increased 
severity of hypoxemia (89). In pediatric patients, there is more 
substantial evidence base for the role of the MMPs in lung injury 
and ARDS. In 2001, two different groups demonstrated elevated 
levels of MMP-8 in the BAL fluid from preterm babies with RDS 
(62, 63) and found that higher amounts of MMP-8 are associated 
with progression from RDS to CLD or bronchoalveolar dysplasia 
(BPD). One group also identified an imbalance between MMP-8 
and its inhibitor, TIMP-1, in the BAL fluid, and lower levels of 
TIMP-1 were associated with hypoxemia and prolonged venti-
lation (62). In pARDS patients, two more recent reports have 
described elevations in BAL fluid MMP-8 and MMP-9 levels 
in ARDS patients relative to controls as well as associations 
between these two proteins and the need for prolonged mechani-
cal ventilation (55, 64). One study also examined the relationship 
between these MMPs and other neutrophil-derived proteinases, 
such as human neutrophil elastase (HNE) and myeloperoxidase 
(MPO), finding positive relationships that may indicate neutro-
phil activity as a major source for the MMP elevations seen in 
ARDS (55).
C-reactive protein (CRP), which is typically highly elevated 
in and used as a marker for acute inflammatory states, has been 
found to be inversely associated with mortality in an adult 
ARDS population (90). However, in a subsequent study of 98 
ventilated pediatric patients with ALI the investigators found 
that higher CRP levels drawn within 48  h of ALI diagnosis 
were associated with mortality and fewer ventilator-free days 
(VFDs) (13). These discordant findings must be interpreted in 
the context of the multiple potential confounding influences in 
the two studies, but also serve to highlight the level of vari-
ability seen in the results of biomarker studies and promote a 
cautious approach in the implementation of clinical decisions 
based on them.
Though many inflammatory cytokines have been studied 
in pARDS, no single one has demonstrated clear superiority 
over others as a single marker for the disease process. IL-6 has 
been most intensely studied, but perhaps a combination of 
cytokines may offer a more complete picture of the inflammatory 
processes active in pARDS. Many of these molecules also have 
specific inhibitors, offering enticing prospects for new treatment 
modalities.
TABLe 2 | Biomarkers in BAL fluid.
Biomarker Full name Finding in children Reference
inflammation
HNE Human neutrophil elastase  – Elevated in nasal secretions of infants with RSV bronchiolitis
 – Non-significant elevation in children with ARDS compared to control
(15, 55)
IL-1 Interleukin 1  – Elevated in infants with RDS and associated with progression to CLD (56, 57)
IL-6 Interleukin 6  – Elevated in healthy neonates subjected to mechanical ventilation
 – Elevated in infants with RDS and associated with progression to CLD
(56, 58–60)
IL-8 Interleukin 8  – Elevated in intubated children with acute lung injury
 – Elevated in preterm infants who progress to CLD
(21, 58)
sL-selectin Soluble L-selectin  – Elevated in infants with RDS who develop BPD (61)
MMP-8 Matrix metalloproteinase 8  – Elevated in children with ARDS
 – Associated with prolonged ventilation in children with ARDS
 – Elevated in infants with RDS and associated with progression to CLD
(55, 62–64)
MMP-9 Matrix metalloproteinase 9  – Elevated in children with ARDS
 – Associated with prolonged ventilation in children with ARDS
 – Elevated in infants with RDS and associated with progression to CLD
(55, 62, 64)
MPO Myeloperoxidase  – Elevated in children with ARDS (55)
TIMP-1 Tissue inhibitor of 
metalloproteinases 1
 – Elevated MMP to TIMP ratios associated with prolonged ventilation in children with ARDS (64)
TIMP-2 Tissue inhibitor of 
metalloproteinases 2
 – Decreased levels in infants with RDS, associated with worse oxygenation and prolonged 
mechanical ventilation
(62)
TNF-α Tumor necrosis factor alpha  – Elevated in healthy neonates subjected to mechanical ventilation (60)
Coagulation and fibrinolysis
PAI-1 Plasminogen activator inhibitor 1  – Elevated in ventilated pediatric patients who develop VAP compared with bacterial 
colonization
(65)
epithelium
CC10/CC16 Clara cell secretory protein  – Correlated with gestational age and with pulmonary infection in neonates (66)
sICAM-1 Soluble intercellular adhesion 
molecule 1
 – Elevated in infants with RDS and associated with progression to CLD (67)
Surfactant proteins
SP-A Surfactant protein A  – Decreased in children with ARDS
 – Decreased in chronic aspiration pneumonitis
 – Decreased in severe RSV bronchiolitis
(68–71)
SP-B Surfactant protein B  – Decreased in children with ARDS
 – Decreased in severe RSV bronchiolitis
(68, 69)
SP-D Surfactant protein D  – Elevated in intubated children with acute lung injury
 – Increased in children with ventilator-associated pneumonia
 – Decreased in chronic aspiration pneumonitis
 – Decreased in severe RSV bronchiolitis
(21, 69, 71, 
72)
Non-protein biomarkers
PGI2 Prostacyclin  – Elevations in infants with RDS associated with decreased oxygen need and decreased 
length of ventilation
(73)
TXB4 Thromboxane B4  – Elevated in ventilated infants who progress to BPD (57)
ARDS, acute respiratory distress syndrome; BPD, bronchopulmonary dysplasia; CLD, chronic lung disease; RDS, respiratory distress syndrome; RSV, respiratory syncytial virus; 
VAP, ventilator-associated pneumonia.
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Coagulation/Fibrinolysis-Related 
Biomarkers
In the classic pathological description of ARDS, the alveolar 
spaces are filled with a proteinaceous complex that forms the 
characteristic hyaline membranes (7). This complex is composed 
of, in large part, fibrin and fibrin breakdown products in addi-
tion to pulmonary edema fluid and inflammatory infiltrates. 
This suggests a role for disordered coagulation homeostasis in 
ARDS and related conditions, and preclinical models support 
the role of pulmonary coagulopathy as a pathologic mechanism 
in ALI (91). Derangements in typical measures of function of 
the coagulation system, such as the prothrombin time (PT) and 
activated thromboplastin time (aPTT), have been associated with 
increased mortality and organ failure in children with ARDS (92). 
Platelets, also critical to the function of the coagulation system, are 
dysregulated in ARDS (93, 94), and thrombocytopenia at ARDS 
onset has been reported to correlate with increased morbidity and 
mortality (95) in both adults and children (96).
However, in addition to these familiar markers of coagulation, 
multiple, more novel biomarkers have been evaluated in children 
with ARDS. Plasminogen activator inhibitor 1 (PAI-1) is an 
antifibrinolytic enzyme that is activated in the setting of inflam-
mation. Depressed fibrinolytic activity, demonstrated by elevated 
PAI-1 levels in the BAL fluid and blood from adults with ARDS, is 
associated with increased mortality and decreased VFDs (97–99). 
PAI-1 has also been evaluated as a marker in pediatric patients, 
and among a cohort of pediatric patients with ARDS, elevated 
plasma PAI-1 was also associated with increased mortality and 
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decreased VFDs (25). Among cohorts of critically ill children, 
PAI-1 levels from BAL fluid were also able to discriminate 
patients with ventilator-associated pneumonia (VAP) compared 
with colonized patients (65), and plasma levels were significantly 
elevated in patients with septic shock, purpura, and ARDS (26). 
In addition to PAI-1, another important regulator of coagulation 
activity in lung disease is soluble urokinase-type plasminogen 
activator receptor (suPAR). This protein binds urokinase (uPA) 
at the cell surface and facilitates the further proteolytic activation 
of plasminogen and pro-uPA, while the soluble form may have 
additional roles in inflammation (100). Plasma suPAR levels were 
elevated in a large study of critically ill, ventilated adults and were 
associated with mortality (101). In a neonatal study, blood suPAR 
levels were elevated among those who developed BPD compared 
with controls, and correlated with disease severity (27). Similarly, 
suPAR levels were shown to correlate with severity in a cohort of 
children with pneumonia, though none of that cohort developed 
ARDS (28). Decreased plasma levels of antithrombin-III, which 
mediates heparin’s anticoagulant effect, early in the course of 
ARDS have also been associated with increased mortality in both 
adults and children (24, 102). Though protein C, an important 
regulator of the activity of thrombin, has been investigated as 
both a biomarker (103) and as a therapeutic agent in the form 
of activated protein C (APC) (104–106) in adult ARDS patients, 
additional studies are needed to clarify its role in children with 
ARDS. Further investigation into biomarkers of coagulation and 
fibrinolysis pathways, including the roles of tissue factor (TF) and 
its pathway inhibitor (TFPI), may further advance our under-
standing of the pathogenesis of ARDS in children and provide 
for new therapeutic targets.
Disturbances of coagulation and fibrinolysis in the setting of 
pARDS are important in the pathogenesis of the disease, espe-
cially as they relate to the function of the microcirculation and 
development of organ failure. PAI-1 and the suPAR pathways 
have the most evidence in children, but more dynamic and 
complete understanding of coagulation pathways will be critical 
to improving outcomes in children.
epithelium-Related Biomarkers
Pulmonary alveolar and bronchial epithelium is an integral 
component of the alveolar–capillary barrier, which is disrupted 
in ARDS. It may be the site of the primary injury, as in direct 
lung injury-mediated ARDS, or may become injured secondarily 
as a result of indirect mechanisms of lung injury (5). Markers 
of epithelial cell injury have been used both as indicators of the 
severity of lung injury as well as for the purpose of differentiation 
between patients with different mechanisms of injury.
A glycoprotein that has been highly associated with epithelial 
cell damage and increased permeability is Krebs von den Lungen-6 
(KL-6) (107). KL-6 is present on alveolar type II pneumocytes 
and can be released in the serum or the alveolar lining fluid (108). 
Elevated KL-6 levels in the blood and in BAL fluid have been 
associated with the development of ARDS (109–111) as well as 
worse ARDS outcomes in adult patients (109, 112, 113). In a study 
of children with ARDS compared with sepsis or traumatic brain 
injury, serum KL-6 was elevated in ARDS patients and higher 
levels were associated with increased mortality (35). In that study, 
KL-6 levels were also correlated with measures of oxygenation, 
length of ventilation, and LOS. Other pediatric studies have 
demonstrated elevated serum KL-6 in infants with bronchiolitis 
(36) or BPD (29, 114), as well as with respiratory complications in 
severely developmentally disabled children (115) and in pediatric 
interstitial lung disease (116).
Clara (also known as club) cell secretory protein (CC16) is a 
protein that is produced and secreted by the Clara cells of the tra-
cheobronchial tree and has been identified as a marker of respira-
tory epithelial injury (117). Elevations in plasma levels of CC16 in 
adult patients have been associated with both the development of 
ARDS (118) as well as with increased mortality and organ failure 
scores when compared with controls (119, 120). However, when 
Ware et  al. compared CC16 levels between patients with ALI 
and those with cardiogenic pulmonary edema they found that 
the ALI patients had comparatively lower BAL fluid and plasma 
CC16 levels, suggesting that CC16 elevations may not be specific 
to ARDS (121). In children, CC16 has been studied primarily as 
a biomarker in neonatal RDS and for the development of BPD. 
However, the results are conflicting. Reports from cord blood 
and postnatal serum found lower levels of CC16 in patients who 
went on to develop BPD (19, 29), while one study demonstrated 
elevated postnatal serum levels in mechanically ventilated infants 
and correlations with progression to BPD (30). Yet, another study 
of tracheal aspirates in preterm infants showed instead a correla-
tion with gestational age as well as elevations in the setting of 
acute infection (66). Though there is significant interest in CC16 
as both a biomarker and as a potential therapy (122), the evidence 
continues to be inconsistent and more study in larger populations 
is needed.
Soluble receptor for advanced glycation end products 
(sRAGE) is a protein that is preferentially expressed on the 
basolateral membrane of alveolar type 1 cells, which are the 
predominant epithelial surface cells in the lung (123). Adults’ 
studies have shown elevations in plasma and BAL fluid sRAGE 
in ARDS (124), and elevated plasma sRAGE is correlated with 
increased mortality, organ failure, and reduced alveolar fluid 
clearance (125, 126). Pediatric studies have demonstrated 
increased plasma sRAGE in patients with bronchiolitis and with 
RDS (37, 38), and plasma sRAGE from pediatric postoperative 
cardiac surgery patients were associated with development of 
ALI as well as with worse oxygenation and longer periods of 
mechanical ventilation (39). It has been noted that BAL fluid 
sRAGE levels may vary inversely with age, which should be 
accounted for in future studies, though no such variations have 
been reported with plasma sRAGE (127).
The alveolar–capillary barrier is also maintained in part by 
cellular adhesion molecules, and one of these proteins that has 
become established as an important marker of both epithelial 
and endothelial integrity is soluble intercellular adhesion 
molecule 1 (sICAM-1) (128–131). In adults, there are multiple 
studies associating blood and BAL fluid sICAM-1 levels with 
the development of ARDS as well as with ARDS outcomes, such 
as mortality (132–134). These findings have been confirmed in 
studies of children, first when Flori et  al. described increased 
mortality in children with ARDS, which was independently 
associated with elevations of sICAM early in the disease course, 
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especially at levels >1000  ng/mL (31). This was reproduced in 
children with ARDS receiving high frequency oscillating ventila-
tion, and further elevations were seen in patients who did not 
respond to lung recruitment maneuvers (32, 33). A recent study 
also demonstrated early increases in sICAM-1 levels in children 
with ALI compared with controls and found associations between 
those levels and both durations of ventilation and mortality (34). 
sICAM has been studied in tracheal aspirates of infants with 
RDS, and concentrations were significantly higher in those who 
went on to develop CLD (67). These findings are highly consist-
ent and underscore the importance of adhesion molecules and 
the pulmonary alveolar–capillary barrier in the pathogenesis of 
pediatric lung injury.
Markers related to the integrity of the pulmonary epithelium 
have strong associations with outcomes and measures of dis-
ease severity in pARDS. KL-6, CC16, sRAGE, and sICAM are 
examples of proteins specific to the epithelium that have shown 
promise as biomarkers and which may prove useful in further 
characterizing subpopulations of children with more severe 
epithelial injury.
endothelium-Related Biomarkers
The endothelium represents the internal side of the alveolar– 
capillary barrier and has been studied extensively as a mediator 
of multiple disease states, including sepsis and ARDS. Pulmonary 
endothelial cells (ECs) are at risk of injury from multiple potential 
sources, both transmitted from external sources through the 
pulmonary epithelium as well as from internal sources through 
the systemic circulation. Endothelial damage and dysfunction 
are thought to be a major mechanism for the development of the 
multi-organ dysfunction that is characteristic of severe ARDS. 
The endothelium has multiple active roles, including production 
of adhesion molecules and cytokines, modulation of vascular 
tone, and management of intravascular coagulation (135).
Several protein biomarkers have been studied as surrogate 
markers for endothelial injury or increased permeability. Von 
Willebrand factor (vWF), a protein involved in platelet function 
produced by ECs and released into the blood upon their acti-
vation or damage, was elevated in the plasma of children with 
ARDS, and early elevation was correlated with mortality and 
decreased VFDs (48). These results were consistent with previous 
findings in infants with RDS (136) as well as with multiple adult 
studies (137–139). Soluble E-selectin is an endothelial leukocyte 
adhesion protein that is upregulated under conditions of inflam-
mation (140). E-selectin levels have been associated with ARDS 
in adults (130, 141, 142), and a recent study reported elevated 
plasma E-selectin levels in children with ARDS compared with 
controls as well as an association with mortality (41). Among 
infants with RDS, plasma E-selectin levels have been associated 
with the development of BPD and were found to decrease with 
dexamethasone therapy (23, 42, 43). L-selectin is another mem-
ber of the selectin family of leukocyte adhesion molecules and is 
expressed primarily on leukocytes (140). Consistent with studies 
in adults (102, 143, 144), L-selectin levels in the plasma of infants 
with RDS are decreased among those patients who develop BPD 
(23) while levels in the BAL fluid are increased, suggesting pos-
sible transmigration of leukocytes into the alveolar space (61). 
Vascular endothelial growth factor (VEGF), which promotes 
endothelial and vascular growth, has also been evaluated in 
neonates with RDS and was found in decreased concentrations 
in patients with severe RDS, while its soluble receptor (sVEGF-R) 
was increased (46). No correlations between BAL fluid VEGF 
levels and disease incidence or severity have been identified in 
studies of infants with RDS or BPD (46, 145).
Another protein that is produced by the pulmonary endothe-
lium as well as other cell types, including epithelium, smooth 
muscle, and immune cells, is endothelin 1 (ET-1). It has gar-
nered interest in ARDS investigations due to pleiotropic effects, 
including potent pulmonary vasoconstriction and stimulation 
of inflammatory responses (146). ET-1 levels were examined in 
two pediatric studies, one in neonates and one in children. The 
neonatal group showed higher cord blood ET-1 levels in infants 
with RDS than controls, and ET-1 levels correlated with longer 
duration of mechanical ventilation (44). The study in children 
with ARDS demonstrated early elevations in ET-1 in affected 
children compared with controls and also found a significant 
association between ET-1 levels in the first 24 h of disease and 
survival (18). These findings are consistent with limited data on 
plasma (147) and BAL (148) ET-1 levels in adult ARDS patients, 
and further research may help guide future investigations of 
potential ET antagonist or inhaled nitric oxide therapies for 
ARDS patients.
Soluble thrombomodulin (sTM) is a circulating protein 
formed as a result of proteolytic cleavage of cellular thrombo-
modulin, a membrane bound protein involved in coagulation and 
inflammatory pathways, and has been identified as a marker of 
endothelial injury (149, 150). Our group has found significant 
relationships between early elevations in plasma sTM and organ 
failure in a large pARDS cohort, and sTM was predictive of 
mortality in a subset of those patients with indirect mechanisms 
of lung injury (45). These findings were consistent with previous 
results from our group in adult patients with ARDS (151) and 
may hint at potential opportunities for endothelial functional 
replacement through the use of recombinant thrombomodulin, 
which has been increasingly used in cases of sepsis and critical 
coagulopathies (152–154).
As a mediator of vascular permeability, angiopoeitin-2 
(Ang-2) may play a significant role in the development of and 
outcomes from ARDS (155). In adults with ARDS, Ang-2 levels 
in the plasma are elevated compared with controls and predict 
mortality in medical and trauma-related ARDS (83, 156–158). 
Though data remain relatively sparse among pediatric patients, 
we recently reported that Ang-2 elevations are associated with 
mortality in pARDS and, additionally, that rising Ang-2 levels 
are highly predictive of mortality among hematopoietic stem cell 
transplant recipients (40).
The endothelium, with its diverse functions involving, among 
others, inflammation, coagulation, and hemodynamics, has a 
central role in the pathobiology of ARDS in children. Markers, 
such as vWF, selectins, ET-1, sTM, and Ang-2, are associated with 
the endothelium in ARDS, each with a different functional impli-
cation. Clinical assessments of these markers will help construct a 
more complete view of the endothelial function and guide future 
therapeutic trials.
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Surfactant Proteins
The surfactant proteins are a group of proteins produced by 
the alveolar type II cells within the lung and secreted as part 
of a complex substance called pulmonary surfactant that serves 
primarily to reduce surface tension in the lung. Alterations or 
damage to the pulmonary surfactant system have been pro-
posed as a mechanism for some of the changes in pulmonary 
physiology seen in ARDS (7, 159). Several studies have exam-
ined surfactant protein levels in pediatric patients with lung 
injury. One large study examining 120 children with respira-
tory failure requiring intubation found lower levels of tracheal 
aspirate surfactant protein A (SP-A) and surfactant protein B 
(SP-B) relative to total aspirate fluid protein in pneumonia and 
ARDS patients compared with controls. SP-A levels were also 
correlated with pulmonary compliance (68). Another, smaller 
study also found decreased normalized levels of SP-A and SP-B 
in BAL fluid from children with ARDS, while surfactant protein 
D (SP-D) was found in elevated amounts with increased break-
down products (21). The same study also evaluated plasma SP 
levels, finding that all three SPs (A, B, and D) were elevated in 
plasma at the time of ARDS diagnosis and that plasma SP-B was 
independently associated with LOS and duration of mechanical 
ventilation. Elevations in BAL fluid SP-D levels have also been 
found in children with VAP compared to ventilated controls 
(72), and plasma SP-D levels are also higher in children with 
bronchopneumonia and associated with increased need for 
supplemental oxygen (49). Similar findings of decreased levels 
of SP-A and SP-B in the BAL fluid were reported in studies of 
infants with severe bronchiolitis (69, 70) but, in contrast to 
other reports, SP-D was also reduced. However, SP-D in the 
serum was elevated in two studies of viral bronchiolitis (50, 51). 
In aggregate, these results seem to suggest a relative depletion 
of pulmonary surfactant proteins and a concomitant increase in 
plasma concentrations, which may relate to increased perme-
ability at the alveolar–capillary barrier. Thus, plasma and BAL 
fluid surfactant concentrations have significant potential as 
biomarkers specific to intrapulmonary processes.
Though trials of surfactant replacement in pARDS have had 
mixed results (160), there are clearly disruptions to the normal 
surfactant system in this disease. Levels of specific surfactant 
proteins in the BAL fluid and blood are associated with clinical 
outcomes, and assessments of these markers in future trials could 
be used to stratify risk and may inform specific replacement 
therapies.
Other Protein Biomarkers
Though the vast majority of biomarker data available in pediat-
rics fall into one of the above categories, several known markers 
do not fit easily into any of them. B-type (formerly known as 
brain-type) natriuretic peptide (BNP or pro-BNP) is a protein 
that has been commonly used to assess fluid status and cardiac 
strain in congestive heart failure and pulmonary hypertension, 
among others. Studies in adults have found that BNP can help dis-
criminate ARDS from cardiogenic pulmonary edema, and higher 
BNP levels are associated with mortality (161–163). Similarly, in 
a cohort of children with ALI, elevated BNP levels early in the 
disease course were associated with worse oxygenation, fewer 
VFDs, increased need for inotropes, and were significantly 
elevated among non-survivors (52). These findings suggest BNP 
as a possible marker of the altered cardiopulmonary interactions 
that can occur in the setting of ALI in children.
Other markers with limited evidence in children with lung 
injury include soluble FAS ligand (sFAS-L) and caspase-1, which 
are involved in the process of programed cell death and were 
elevated among infants with RSV bronchiolitis compared with 
controls (53). Though there are some data to support a role for 
soluble FAS and sFAS-L in adult ARDS (164, 165), the utility of 
these two markers in pARDS remains unclear.
Non-Protein Biomarkers
Though much of the investigation devoted to the identification 
of biomarkers in ARDS has been focused on proteins, a great 
deal of progress has also been made in the area of non-protein 
biomarkers. These non-protein markers are quite varied, but 
can be generally categorized into lipid-based molecules, nucleic 
acids, microparticles (MPs), and extracellular complexes. We will 
discuss each of these categories briefly.
Lipid biomarkers comprise a heterogeneous group of hydro-
phobic molecules that have multiple and varied roles in normal 
bodily functions. One group of these that has been investigated 
in more detail in the setting of ARDS is the eicosanoids, which 
are generated through metabolism of 20-carbon fatty acids, such 
as arachidonic acid. These include prostaglandins (PGs), leukot-
rienes (LTs), thromboxane (TXA), and others, many of which 
have potential effects involving vascular, endothelial, platelet, and 
leukocyte function. Thromboxane A2 (TXA2) and prostacyclin 
(PGI2) (also known as prostaglandin I2) are produced in the lung 
and have effects on pulmonary vascular resistance, with TXA2 
promoting pulmonary vasoconstriction and PGI2 vasodilation 
(166). In several studies of at risk adults (167–169), TXA levels 
were elevated in patients who developed ARDS, as was the TXA 
to prostaglandin ratio. Indeed, elevations in BAL fluid TXA B2, 
an active metabolite of TXA2, are associated with progression to 
BPD in infants with lung inflammation and RDS (57), while eleva-
tions in PGI2 seem to have a beneficial relationship (73). An early 
study of RDS also reported elevations in plasma prostaglandin 
E (PGE) and prostaglandin F (PGF) with a low PGE:PGF ratio 
(54). Elevated levels of LT B4, C4, and D4 have been detected in the 
blood and BAL fluid from adult patients with ARDS (170, 171), 
and leukotriene B4 has been associated with mortality (81, 172). 
In children, these molecules have largely been studied in the set-
ting of neonatal RDS and the development of BPD. Elevations of 
urinary leukotriene E4 have been associated with ARDS in adults 
(173) and development of BPD in infants (174, 175), though 
variations observed may be highly affected by gestational age and 
maturity (176). Several studies of neonates have demonstrated 
alterations in the levels of markers of oxidative stress and DNA 
damage in RDS (175, 177), and one study of BAL fluid in children 
with ALI found alterations in the concentrations of multiple cell 
surface lipids indicative of alveolar–capillary membrane damage 
(21). Eicosanoids and other lipid-derived and small molecules 
may serve as useful biomarkers, especially of vascular physiology, 
oxidative damage, and inflammation, in future studies of children 
with ARDS.
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Advances in genetic science and technology have enabled 
research into the feasibility of using nucleic acid-based biomarker 
assays in acute illness. Major targets have been small RNA 
molecules, such as micro-RNAs (miRNAs), which, due to their 
abundance in the blood and other body fluids as well as their 
relative resistance to degradation, may have utility as biomarkers 
(178). miRNAs have a predictable structure and have variable 
expression patterns depending on the body site and physiologic 
conditions. miRNAs perform important functional roles in cellu-
lar function through their ability to regulate translation of specific 
gene products at the mRNA level, and a single miRNA species 
may have multiple gene targets (178). Another notable feature of 
miRNAs is that they have potential as therapeutic targets due to 
their ability to be regulated by antisense versions of themselves, 
or antagomiRs. Though many miRNAs have been identified as 
possible contributors to or markers of lung diseases, clinical data 
in humans with ARDS are extremely limited (179, 180). This is a 
fertile area for further study in children with ARDS.
Additional types of non-protein biomarkers that may have 
utility in pediatric lung disease include several types of extra-
cellular complexes, including circulating MPs (also known as 
microvesicles or cellular exosomes) and neutrophil extracellular 
traps (NET). MPs are a class of cell-derived vesicles that develop 
by budding off from the membrane of many different cell types 
and range in size from 50 nm to 1 μm. They may carry a variety 
of different contents, including proteins, lipids, and nucleic acids, 
and have a wide variety of potential effects in lung injury depend-
ing on their origin, location, and contents (181). MPs have been 
isolated from the blood (182) and BAL fluid (183) in adult ARDS 
patients and have been subtyped based on their cellular origin 
with certain subtypes, such as leukocyte-derived MPs, demon-
strating possible prognostic significance. MP-based biomarkers 
may prove useful in future studies of children with ARDS and 
may also have potential as therapeutic agents able to ferry pay-
loads of drugs or other substances to specific target tissues based 
molecular tropism (184). NETs are derived from programed 
death of circulating neutrophils and are composed of extruded 
cellular contents, including nuclear chromatin, histone proteins, 
and other various proteins. These NETs have antimicrobial activ-
ity and have been proposed as a host defense mechanism (185). 
NETs have been detected in the plasma and BAL of patients with 
transfusion-related acute lung injury (TRALI) (186) and critical 
illnesses (187), and circulating extracellular histones, the major 
protein component of NETs, are directly cytotoxic and elevated 
in the setting of trauma-associated lung injury (188). NETs, MPs, 
and other extracellular complexes represent potentially useful 
biomarkers in children with ARDS.
DiSCUSSiON
Since the initial description of ARDS, there have been widespread 
investigations into the pathobiology of the syndrome as well as for 
better ways to care for its victims. Through the increasing use of 
molecular techniques for the study of the ARDS disease process, 
we have gained a great deal of knowledge related to the develop-
ment, progression, and resolution of this devastating condition. 
One major hope for the application of this knowledge is to further 
characterize subpopulations within what is widely regarded as an 
extremely heterogeneous disease, which may then lead to the 
development of specific therapies tailored toward the pathophysi-
ological changes found in each subpopulation. Preliminary steps 
in this process were realized recently with the description of a bio-
marker “panel” for ARDS (83) and the publication of a latent class 
analysis of two ARDS clinical trials by Calfee et al. who described 
two subphenotypes, hyper- and hypo-inflammatory, with dif-
ferential clinical responses to the trial interventions (189). These 
findings were based on the analysis of clinical characteristics and 
multiple biomarkers and hold promise that further subphenotyp-
ing might be used to guide the design of future clinical trials, such 
as those targeting Th2 high vs. Th2 low populations in asthma 
(190). Though no clear ARDS subphenotypes have yet been iden-
tified in pediatric patients, it would seem that the same principles 
could reasonably be applied. It is also important to recognize that 
information from biomarkers in pARDS may provide value both 
in terms of their ability to improve risk stratification and also to 
better define the pathophysiology of this heterogeneous condi-
tion. Better risk stratification will allow for well-designed trials 
of pARDS therapies and improved prognostication for families. 
In counterpoint, improved understanding of the pathological 
mechanisms that lead to pARDS and regulate its resolution may 
form the bases for the development of novel therapies.
New types of biomarkers, such as non-protein and nucleic acid-
based biomarkers, are potentially rich sources of information that 
remain relatively untapped in pediatric populations. Challenges 
remain, especially in the technical aspects of isolating, character-
izing, and quantifying non-protein biomarkers in large numbers 
of children with ARDS. However, technological advancement, 
especially in the realm of nucleic acid sequencing with polymerase 
chain reaction (PCR)-based methods, has dramatically reduced 
both the price and processing time for assays of genetic material. 
Methods for large-scale isolation of lipid vesicle-based MPs are 
not yet well-developed but will certainly improve in the coming 
years. Both nucleic acids and lipid vesicles are very appealing as 
both markers and as potential therapeutic agents, as they have 
potential to act through tissue and biochemical pathway-specific 
mechanisms that may increase potency and decrease unwanted 
side effects. Non-protein biomarkers thus represent a significant 
field for future research in pARDS.
There are many remaining difficulties in the pursuit of accu-
rate and useful biomarker-based models in pARDS. One major 
challenge has been the establishment and widespread use of 
common diagnostic criteria for ARDS in children. Though con-
sensus criteria have been available for decades in adults (4, 5), a 
pediatric-specific definition for ARDS, now referred to as pARDS, 
was only published in 2015 (6). This definition expands upon the 
adult Berlin definition to allow for criteria that are more clinically 
relevant to pediatrics, such as unilateral radiographic infiltrates 
and pulse oximetry-based oxygenation metrics. It also utilizes the 
oxygenation index (OI), which has been well-validated in pediat-
ric lung disease, as a risk stratification tool. This definition, as it 
becomes widely adopted, will help to improve the comparability 
between pediatric studies of ARDS, especially as the OI reflects 
not only the fraction of inspired oxygen but also the mean airway 
pressure support. Future studies of ARDS biomarkers in children 
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should therefore strive to abide by these definitions, and indeed, 
many of the previously identified biomarkers of ARDS in children 
likely should be revalidated using the new pARDS criteria.
By definition, biomarkers are found and measured in body 
fluids and tissues. Therefore, to measure them, it is necessary 
to collect biological samples from some of our societies’ most 
vulnerable members. Children are more sensitive to collections 
of large volume samples than adults, and parents are often wary 
to allow their sick children to participate in clinical research. 
Fortunately, over recent years, many improvements in assay 
technology have allowed the development of multiplex assays 
that can measure dozens of proteins and other biomarkers in a 
single fluid sample, greatly improving the information yield from 
limited patient populations.
Technologies like these can help overcome a major challenge 
pARDS research, which is the overall paucity of data. However, 
this will also require a concerted effort toward collaboration 
between many researchers and institutions to expand the avail-
able pool of data. The systems of incentives in place for funding 
and promotion must also be reexamined to support collaborative 
research in addition to individual projects. Research groups, such 
as the Pediatric Acute Lung Injury and Sepsis Investigators1 and 
the Collaborative Pediatric Critical Care Research Network,2 
among others, must continue to expand and share their data-
bases of biomarker data to facilitate new insights and generate 
hypotheses for new clinical trials. Larger data sets may allow for 
improvements in sensitivity and specificity, as well as expand the 
external validity of, known biomarkers such that meaningful 
clinical tools or scores could be developed around them. However, 
in order to make use of these large data sets pediatric researchers 
will need to embrace the growing field of biomedical informatics. 
Large-scale information analysis can utilize complex algorithms 
and machine learning to efficiently detect patterns and sub-
populations that would be otherwise invisible with conventional 
techniques. However, this requires dedicated resources and data 
access that is best suited to collaborative networks. No pARDS 
biomarker has yet achieved the clinical utility of creatinine for 
1 www.palisi.org
2 www.cpccrn.org
kidney injury or troponin for myocardial infarction, but with 
large-scale collaboration and data analysis the chance of success 
grows dramatically.
Data gleaned from biomarker testing may offer some of the 
most timely and valuable diagnostic and prognostic informa-
tion available in the setting of ARDS. This is especially true in 
pediatric medicine, where invasive diagnostic procedures, such as 
bronchoscopy and biopsy, as well as radiation exposure related to 
diagnostic imaging, are limited as much as possible. In the setting 
of low mortality in pARDS, biomarkers or panels thereof may also 
be valuable in therapeutic trials as clinically and physiologically 
meaningful surrogate outcomes. Biomarkers data are used for 
accurate diagnosis and guidance of treatment in wide and varied 
medical conditions, but efforts to expand their use in pARDS 
continue to suffer from challenges due to the relatively low inci-
dence of the disease, standardization of diagnostic criteria and 
measurement techniques, and funding limitations. Collaboration 
between nations and institutions is essential for replication of ini-
tial results, continued innovation, and to expand the applicability 
of findings to more diverse pediatric populations.
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